Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Grand Pharmaceutical Group Limited ( (HK:0512) ).
Grand Pharmaceutical Group has secured approval from China’s National Medical Products Administration for GPN01768, the lotilaner ophthalmic solution TP-03, as the first commercial treatment nationwide for Demodex blepharitis. The drug, already the only approved therapy for this condition globally and a strong revenue contributor in the United States, now anchors the group’s strategy to expand its ophthalmic footprint across the Greater China region.
The NMPA’s “zero supplementation request” decision accelerates commercialization in mainland China and follows earlier approval in Macao, with filings in Hong Kong and Taiwan to follow, positioning the product to address a vast, previously untreated patient base estimated at over 40 million. Together with a pipeline of late-stage ophthalmic and ENT innovations expected to launch from 2026, the approval is set to deepen Grand Pharmaceutical’s differentiated competitive edge, open new high-growth market segments and support long-term, innovation-led expansion for the company and its stakeholders.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$8.50 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Bermuda-incorporated healthcare company focused on innovative drugs, with ophthalmology as a key strategic pillar. The group is building a professional, full-series ophthalmic portfolio spanning dry eye, Demodex blepharitis, post-surgical anti-inflammatory and analgesic therapies, pterygium and myopia, targeting major unmet clinical needs in China and the broader Greater China region.
Leveraging a model that combines in-licensed global innovations with in-house R&D, Grand Pharmaceutical is advancing multiple late-stage candidates, including hormone nanosuspension eye drops GPN00833, pterygium therapy GPN00153 and pediatric myopia drug GPN00884. It is also preparing to roll out additional innovative products such as Varenicline Tartrate Nasal Spray, Ryaltris and Neffy to reinforce its position across ophthalmology and related ENT indications.
Average Trading Volume: 4,826,680
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.53B
See more insights into 0512 stock on TipRanks’ Stock Analysis page.